Analyst views clinical results as central to Bavarian Nordic's external financing

Danish senior analyst Søren Løntoft Hansen views phase I/II results to be key in Bavarian Nordic's efforts to attain external financing.

Photo: Sydbank/PR

The Danish bank Sydbank sees positive aspects to Bavarian Nordic's Monday announcement that it has received a positive batch of data on the vaccine candidate ABNCovid2 against Covid-19 and will soon commence in-human studies.

Before long, phase I/II will start including humans as it is carried out at the Radboud University Medical Center in the Netherlands.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs